Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event.
Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.
Mitul D
MD
Gandhi
Andrew M
AM
Evens
Timothy S
TS
Fenske
Paul
P
Hamlin
Bertrand
B
Coiffier
Andreas
A
Engert
Alison J
AJ
Moskowitz
Nilanjan
N
Ghosh
Adam M
AM
Petrich
Jon
J
Lomasney
Amy
A
Chadburn
Gary S
GS
Wood
Katrin
K
Salva
Beatrice
B
Nardone
Steven M
SM
Trifilio
Dennis W
DW
Raisch
Dennis P
DP
West
Leo I
LI
Gordon
Jane N
JN
Winter
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001344:Autopsy; D000079963:Brentuximab Vedotin; D017809:Fatal Outcome; D005260:Female; D006689:Hodgkin Disease / Q000150:complications / Q000188:drug therapy; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects* / Q000627:therapeutic use; D017728:Lymphoma, Large-Cell, Anaplastic / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D010195:Pancreatitis / Q000139:chemically induced* / Q000473:pathology; D016896:Treatment Outcome; D055815:Young Adult
D000970:Antineoplastic Agents; D018796:Immunoconjugates; D000079963:Brentuximab Vedotin